Raras
Buscar doenças, sintomas, genes...
Síndrome Rett
ORPHA:778CID-10 · F84.2CID-11 · LD90.4OMIM 312750DOENÇA RARA

Distúrbio grave do desenvolvimento neurológico que afeta o sistema nervoso central.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Distúrbio grave do desenvolvimento neurológico que afeta o sistema nervoso central.

Pesquisas ativas
28 ensaios
98 total registrados no ClinicalTrials.gov
Publicações científicas
4.430 artigos
Último publicado: 2026 Apr 21
Medicamentos
11 registrados
DEXTROMETHORPHAN, RISPERIDONE, DONEPEZIL HYDROCHLORIDE

Tem tratamento?

11 medicamentos registrados
Ver detalhes, fases e interações →
DEXTROMETHORPHANRISPERIDONEDONEPEZIL HYDROCHLORIDECANNABIDIOLDONEPEZILKETAMINEMECASERMINVATIQUINONESARIZOTANLOVASTATIN

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
10.0
Europe
Início
Infancy
🏥
SUS: Cobertura mínimaScore: 20%
Centros em: PA, PR, SC, RS, ES +10CID-10: F84.2
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
12 sintomas
🦴
Ossos e articulações
4 sintomas
💪
Músculos
3 sintomas
📏
Crescimento
3 sintomas
🫁
Pulmão
2 sintomas
🫃
Digestivo
2 sintomas

+ 31 sintomas em outras categorias

Características mais comuns

100%prev.
Início na infância
Obrigatório (100%)
100%prev.
Regressão do desenvolvimento
Frequência: 3/3
100%prev.
Convulsão
Obrigatório (100%)
100%prev.
Torção estereotipada das mãos
Frequência: 3/3
100%prev.
Deterioração motora
Frequência: 2/2
100%prev.
Deficiência intelectual, profunda
Frequência: 2/2
57sintomas
Muito frequente (14)
Frequente (11)
Ocasional (13)
Muito raro (1)
Sem dados (18)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 57 características clínicas mais associadas, ordenadas por frequência.

Início na infânciaChildhood onset
Obrigatório (100%)100%
Regressão do desenvolvimentoDevelopmental regression
Frequência: 3/3100%
ConvulsãoSeizure
Obrigatório (100%)100%
Torção estereotipada das mãosStereotypical hand wringing
Frequência: 3/3100%
Deterioração motoraMotor deterioration
Frequência: 2/2100%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico4.430PubMed
Últimos 10 anos200publicações
Pico2025138 papers
Linha do tempo
2026Hoje · 2026🧪 1993Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: X-linked dominant.

MECP2Methyl-CpG-binding protein 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Chromosomal protein that binds to methylated DNA. It can bind specifically to a single methyl-CpG pair. It is not influenced by sequences flanking the methyl-CpGs. Mediates transcriptional repression through interaction with histone deacetylase and the corepressor SIN3A. Binds both 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC)-containing DNA, with a preference for 5-methylcytosine (5mC)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (7)
MECP2 regulates transcription of neuronal ligandsRegulation of MECP2 expression and activityMECP2 regulates neuronal receptors and channelsMECP2 regulates transcription factorsTranscriptional Regulation by MECP2
MECANISMO DE DOENÇA

Angelman syndrome

A neurodevelopmental disorder characterized by severe motor and intellectual retardation, ataxia, frequent jerky limb movements and flapping of the arms and hands, hypotonia, seizures, absence of speech, frequent smiling and episodes of paroxysmal laughter, open-mouthed expression revealing the tongue.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
38.8 TPM
Cerebelo
34.5 TPM
Útero
28.9 TPM
Artéria tibial
28.1 TPM
Fallopian Tube
27.9 TPM
OUTRAS DOENÇAS (8)
syndromic X-linked intellectual disability Lubs typeRett syndromeX-linked intellectual disability-psychosis-macroorchidism syndromesevere neonatal-onset encephalopathy with microcephaly
HGNC:6990UniProt:P51608

Medicamentos e terapias

DEXTROMETHORPHANPhase 3

Mecanismo: Glutamate [NMDA] receptor subunit epsilon 1 antagonist

RISPERIDONEPhase 3

Mecanismo: Serotonin 2a (5-HT2a) receptor antagonist

DONEPEZIL HYDROCHLORIDEPhase 3

Mecanismo: Acetylcholinesterase inhibitor

CANNABIDIOLPhase 3

Mecanismo: Cannabinoid CB1 receptor negative allosteric modulator

DONEPEZILPhase 3

Mecanismo: Acetylcholinesterase inhibitor

KETAMINEPhase 2

Mecanismo: Glutamate [NMDA] receptor negative allosteric modulator

MECASERMINPhase 2

Mecanismo: Insulin-like growth factor I receptor agonist

VATIQUINONEPhase 2

Mecanismo: Quinone reductase 1 modulator

SARIZOTANPhase 2

Mecanismo: Dopamine D4 receptor agonist

LOVASTATINPhase 2

Mecanismo: HMG-CoA reductase inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

1,419 variantes patogênicas registradas no ClinVar.

🧬 MECP2: NM_001110792.2(MECP2):c.961C>G (p.Arg321Gly) ()
🧬 MECP2: GRCh38/hg38 Xq28(chrX:153958631-154171022)x2 ()
🧬 MECP2: GRCh38/hg38 Xq26.3-28(chrX:137491159-155700385)x2 ()
🧬 MECP2: GRCh38/hg38 Xq28(chrX:153828334-154347735)x2 ()
🧬 MECP2: NM_001110792.2(MECP2):c.1196_1220delinsTCAAGTC (p.Pro399_Glu406delinsLeuLys) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 1,178 variantes classificadas pelo ClinVar.

942
177
59
Patogênica (80.0%)
VUS (15.0%)
Benigna (5.0%)
VARIANTES MAIS SIGNIFICATIVAS
MECP2: NM_001110792.2(MECP2):c.1181_1235del (p.Leu394fs) [Pathogenic]
MECP2: NM_001110792.2(MECP2):c.281_284dup (p.Arg96fs) [Likely pathogenic]
MECP2: NM_001110792.2(MECP2):c.1122_1229delinsAAGAAGGAGCACCACCATCACCACCACTCAGAGT (p.Lys... [Likely pathogenic]
MECP2: NM_001110792.2(MECP2):c.1053dup (p.Lys352Ter) [Likely pathogenic]
MECP2: NM_001110792.2(MECP2):c.708_724dup (p.Pro242fs) [Pathogenic]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 38
2Fase 27
1Fase 11
·Pré-clínico14
Medicamentos catalogadosEnsaios clínicos· 10 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Síndrome Rett

Centros de Referência SUS

24 centros habilitados pelo SUS para Síndrome Rett

Centros para Síndrome Rett

Detalhes dos centros

Hospital Universitário Prof. Edgard Santos (HUPES)

R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital Infantil Albert Sabin

R. Tertuliano Sales, 544 - Vila União, Fortaleza - CE, 60410-794 · CNES 2407876

Serviço de Referência

Rota
Anomalias CongênitasDeficiência Intelectual

Hospital de Apoio de Brasília (HAB)

AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)

Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital das Clínicas da UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital Universitário da UFJF

R. Catulo Breviglieri, Bairro - s/n - Santa Catarina, Juiz de Fora - MG, 36036-110 · CNES 2297442

Atenção Especializada

Rota
Anomalias Congênitas

Hospital das Clínicas da UFMG

Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Julio Müller (HUJM)

R. Luis Philippe Pereira Leite, s/n - Alvorada, Cuiabá - MT, 78048-902 · CNES 2726092

Atenção Especializada

Rota
Anomalias Congênitas

Hospital Universitário João de Barros Barreto

R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Lauro Wanderley (HULW)

R. Tabeliao Estanislau Eloy, 585 - Castelo Branco, João Pessoa - PB, 58050-585 · CNES 0002470

Atenção Especializada

Rota
Anomalias Congênitas

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Pequeno Príncipe

R. Des. Motta, 1070 - Água Verde, Curitiba - PR, 80250-060 · CNES 3143805

Serviço de Referência

Rota
Anomalias CongênitasDeficiência Intelectual

Hospital Universitário Regional de Maringá (HUM)

Av. Mandacaru, 1590 - Parque das Laranjeiras, Maringá - PR, 87083-240 · CNES 2216108

Atenção Especializada

Rota
Anomalias Congênitas

Hospital de Clínicas da UFPR

R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Pedro Ernesto (HUPE-UERJ)

Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)

Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital São Lucas da PUCRS

Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Clínicas de Porto Alegre (HCPA)

Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário da UFSC (HU-UFSC)

R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da FMUSP

R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Base de São José do Rio Preto

Av. Brg. Faria Lima, 5544 - Vila Sao Jose, São José do Rio Preto - SP, 15090-000 · CNES 2079798

Atenção Especializada

Rota
Anomalias Congênitas

Hospital de Clínicas da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas de Ribeirão Preto (HCRP-USP)

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

UNIFESP / Hospital São Paulo

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo
Sobre os centros SUS: Estes centros são habilitados pelo Ministério da Saúde como Serviços de Referência em Doenças Raras ou Serviços de Atenção Especializada. O atendimento é pelo SUS, com encaminhamento da rede de atenção básica.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

18 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

98 ensaios clínicos encontrados, 28 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
2.068 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 2.068

#1

Dysregulated Cholesterol Clearance via CYP46A1 Contributes to Cerebellar Sterol Imbalance in Mecp2-Null Mice.

International journal of molecular sciences2026 Mar 03

Rett syndrome (RTT) is a neurodevelopmental disorder characterized by motor deficits, partly attributed to cerebellar dysfunction. RTT is primarily caused by mutations in the gene encoding the methyl-CpG-binding protein 2 (MECP2), which has been implicated in cholesterol homeostasis by mechanisms that remain poorly understood. Given that brain cholesterol is primarily synthesized de novo and that disrupted cholesterol homeostasis is linked to various neurological disorders, we aimed to investigate cholesterol regulation in the cerebellum of Mecp2-null mice, a well-established RTT model. We measured total cholesterol levels in cerebellar tissue and cerebellar synaptosomes and assessed the expression of genes involved in cholesterol biosynthesis and intracellular transport. Our results show significantly elevated total cholesterol in both cerebellar tissue and synaptosomes. Furthermore, we identified a marked reduction in CYP46A1 expression, which is essential for the elimination of encephalon sterols. In contrast, key cholesterol biosynthetic regulators (Srebp2, Hmgcs1, Sqle) showed no significant changes in expression, suggesting an impaired cerebellar cholesterol turnover-driven by defective clearance-rather than enhanced synthesis may underlie the metabolic imbalance observed in the cerebellum of the RTT mouse model. Altogether, these findings provide a mechanistic insight into how MeCP2 deficiency disrupts cerebellar cholesterol homeostasis and highlight cholesterol clearance pathways as potential contributors to RTT pathology and a factor to consider for further RTT therapeutic approaches.

#2

MECP2-Associated Rett Syndrome Without Developmental Regression-A Case Series.

Journal of child neurology2026 Mar 12

Clinical phenotype expansion of neurodevelopmental disorders is increasingly important. With accessibility and diagnostic ability of genetic testing expanding, new clinical criteria will continue to be elucidated. Here we describe a case series of 4 female pediatric patients seen for global developmental delay in non-genetic, specialty clinics who received unexpected genetic diagnoses of MECP2-associated Rett syndrome (RS). These results highlight broadening clinical presentation for RS. None of the patients in this cohort met clinical RS diagnostic criteria at the time of genetic testing, as there was no period of typical development or developmental regression. These cases demonstrate both the importance of broad genomic sequencing for patients with global developmental delay and that increasing understanding of atypical and mild presentations of syndromes like RS will continue to evolve as genetic testing becomes standard of care for clinical features like developmental delay.

#3

A KCNC1 variant linked to Rett syndrome disrupts ER to Golgi trafficking of Kv3.1 channel.

Proceedings of the National Academy of Sciences of the United States of America2026 Mar 17

Intrinsic neuronal excitability, defined by the balance between input and output signals, is crucial to neural function, and its disruption underlies various neurological diseases. Kv3.1 channels, encoded by KCNC1, are essential for high-frequency action potential firing. Variants in these channels are associated with several subtypes of epilepsy. We report a patient with developmental regression and epilepsy, meeting Rett syndrome criteria, who carries a KCNC1 variant encoding the S474C substitution in Kv3.1 (Kv3.1S474C). Electrophysiological and biochemical assays reveal that Kv3.1S474C reduces channel presence in the plasma membrane and is retained in the endoplasmic reticulum. In murine primary cortical neuron cultures expressing Kv3.1S474C, we observed reduced neuronal firing frequency and exclusion of the channel from the axon initial segment. Consistently, we found a decreased firing frequency using a conductance-based computational neuronal model. In summary, this study identifies a link between a KCNC1 variant and Rett syndrome, highlighting the importance of S474 residue in Kv3.1 channel trafficking and function in neurons.

#4

A novel heterozygous pathogenic variation in the MECP2 gene causing typical Rett syndrome: a case report.

Translational pediatrics2026 Feb 28

Rett syndrome (RTT) is an X-linked neurodevelopmental disease with clear diagnostic criteria and mainly affects females. Mutations of the methyl-CpG-binding protein 2 (MECP2) gene cause most RTT cases. While numerous MECP2 mutations have been reported, the pathogenicity of novel identified variants often requires functional validation. To obtain a definite genetic diagnosis result and determine the specific pathogenesis, it is essential to conduct functional validation of the novel mutation. We reported one clinical case of a female child diagnosed with typical RTT. The patient presented with major clinical manifestations, including hand dyspraxia, loss of language ability, stereotypical hand movements, and an abnormal gait. Whole-exome sequencing (WES) was performed on this Chinese trio, which confirmed a novel heterozygous nonsense mutation in exon 1 of the MECP2 gene in the proband. Sanger sequencing confirmed that neither parent carried this variant. Functional validation experiments demonstrated that cells transfected with the mutant recombinant plasmid showed significantly reduced levels of both MECP2 messenger RNA (mRNA) and protein compared to those transfected with the wild-type plasmid. These functional findings confirm the pathogenicity of this de novo MECP2 nonsense mutation and demonstrate that it leads to a loss of function, a mechanism consistent with nonsense-mediated mRNA decay (NMD). Our study elucidates the genotype-phenotype correlation in this case and provides experimental insight into the underlying molecular mechanism.

#5

Safety and effectiveness of diazepam nasal spray in patients with Rett syndrome and seizure clusters: post hoc analyses from a long-term safety study and survey of severity and burden.

Frontiers in neurology2026

Rett syndrome is a neurodevelopmental disorder associated with epilepsy that influences motor/communication skills, behavior, and other systems. Clinical experiences for these patients are not well described. This post hoc analysis consists of a patient subgroup with Rett syndrome enrolled in an open-label, single-arm, safety study. Age- and weight-based doses of diazepam nasal spray (5-20 mg) were administered to patients (aged 6-65 years) for seizure clusters. Treatment-emergent adverse events (TEAEs) were recorded, and days between seizure clusters (SEIzure interVAL [SEIVAL]) from Period 1 (P1; days 1-90) to Period 4 (P4; days 271-360) were calculated. Caregivers completed surveys describing experiences with diazepam nasal spray and Rett syndrome. Rates of TEAEs (87.5%), serious TEAEs (12.5%), and treatment-related TEAEs (18.8%) in patients with Rett syndrome (n = 16) who received diazepam nasal spray were comparable to the overall pediatric safety population (87.2, 35.9, and 14.1%, respectively; n = 78), as was use of second doses (proxy for effectiveness) (18.4 and 11.4%). Increase in SEIVAL was also similar (P1 = 7.6, P4 = 25.0 days and P1 = 13.0, P4 = 25.9 days). Most (n = 12; 75.0%) remained in the study ≥12 months. All caregivers felt diazepam nasal spray was very/extremely easy to use; 63.6% were able to return to normal activities within an hour of administration. Caregiver perceptions of clinical severity and caregiver affect were stable from baseline to final visits; scores for individuals using diazepam nasal spray were numerically higher. Diazepam nasal spray has safety and effectiveness profiles consistent with the full study population and was easy to use. ClinicalTrials.gov, NCT02721069.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC2.859 artigos no totalmostrando 191

2026

Exon skipping to treat Rett syndrome.

Nature reviews. Drug discovery
2026

Design, synthesis and evaluation of trofinetide prodrug based on diketopiperazine strategy.

Bioorganic &amp; medicinal chemistry
2026

mPFC pyramidal neuron synchrony during social competition to form social rankings is disrupted in male Mecp2 knockout mice.

bioRxiv : the preprint server for biology
2026

Dysregulated Cholesterol Clearance via CYP46A1 Contributes to Cerebellar Sterol Imbalance in Mecp2-Null Mice.

International journal of molecular sciences
2026

Trajectory of skill acquisition, loss, and regain in females with classic Rett syndrome.

Journal of neurodevelopmental disorders
2026

MECP2-Associated Rett Syndrome Without Developmental Regression-A Case Series.

Journal of child neurology
2026

A KCNC1 variant linked to Rett syndrome disrupts ER to Golgi trafficking of Kv3.1 channel.

Proceedings of the National Academy of Sciences of the United States of America
2026

A novel heterozygous pathogenic variation in the MECP2 gene causing typical Rett syndrome: a case report.

Translational pediatrics
2026

Safety and effectiveness of diazepam nasal spray in patients with Rett syndrome and seizure clusters: post hoc analyses from a long-term safety study and survey of severity and burden.

Frontiers in neurology
2026

[Features of premorbid status in patients with Rett syndrome].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2026

Modulating alternative splicing of MECP2 is a potential therapeutic strategy for Rett syndrome.

Science translational medicine
2026

Image-based epigenetic profiling with deep learning and high-speed super-resolution microscopy.

Epigenetics &amp; chromatin
2026

A Developmental Study of MeCP2 with Core and Linker Histones Indicates a Dynamic Change During Adolescent Brain Development in a Region- and Strain-Specific Manner in Mice.

Biomolecules
2026

'Molecular and Cellular Neuroscience': Impacts of Eight Highly Cited Articles Published in This Section of Brain Sciences in 2024.

Brain sciences
2026

Sociodemographic Profiles and Age-Related Differences in Comorbidities, Sleep, and Quality of Life of Turkish Children with Rett Syndrome and their Families.

Neuropediatrics
2026

MECP2 MBD-ID Module: A Unified DNA/RNA Binding Interface Disrupted in Rett Syndrome.

bioRxiv : the preprint server for biology
2026

Global trends and future perspectives in autism spectrum disorder and gut microbiota research: a comprehensive bibliometric analysis.

Frontiers in neuroscience
2026

Use of fenfluramine in MECP2-related Rett syndrome: Findings from a retrospective multicenter pediatric case series.

Epilepsy &amp; behavior : E&amp;B
2026

Proteomic dataset of MECP2-deficient and wild-type human brain organoids under spaceflight and ground conditions.

Scientific data
2026

miR126-mediated alteration of vascular integrity in Rett syndrome.

Molecular psychiatry
2025

Longitudinal trajectory of gross motor skills in school-aged children with Rett syndrome.

Frontiers in neurology
2026

The Nodding syndrome cerebrospinal fluid proteome: a lens into neurodevelopmental failure consistent with environmentally triggered MECP2 dysregulation?

Frontiers in molecular neuroscience
2026

Pediatric intestinal pseudo-obstruction found in 3-year-old male with Rett-related mutation of methyl-CpG binding protein 2.

JPGN reports
2026

MECP2 Gene-Related Severe Neonatal Encephalopathy: A Rare Case in a Female Neonate.

Cureus
2026

MECP2 Insufficiency Attenuates RUNX2-Dependent Osteoblast Differentiation via miR-126-3p/DKK1-Mediated Canonical Wnt Signaling Inhibition in Rett Syndrome.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2026

The serotonin receptor 7 as an emerging target to restore altered neuroplasticity in Angelman syndrome.

Experimental neurology
2026

A Translational Roadmap for Neurological Nonsense Mutation Disorders.

International journal of molecular sciences
2026

A Phase 1, Randomized, Open-Label Study to Assess the Bioequivalence of Trofinetide as a Ready-to-Use Oral Solution and Constituted Powder for Oral Solution in Healthy Adults.

Advances in therapy
2026

Dendrimer-Conjugated Glutamine Antagonist, D-TTM020, Ameliorates Brain Immune Dysregulation and Improves Neurobehavioral Deficits in the Mecp2-Deficient Mouse Model.

Cells
2026

Mortality Among Youth and Young Adults With Autism Spectrum Disorder, Intellectual Disability, or Cerebral Palsy.

JAMA pediatrics
2026

Transcranial Photobiomodulation in Rett Syndrome: A Mechanistic Review and Therapeutic Hypothesis.

Photobiomodulation, photomedicine, and laser surgery
2026

IGF1 peptide targets Rett Syndrome astrocytes to degrade IGF binding protein, rescue synaptogenesis and restore mitochondrial function.

bioRxiv : the preprint server for biology
2026

Unconstrained Plasticity Disrupts Memory Consolidation in a Mouse Model of Rett Syndrome.

bioRxiv : the preprint server for biology
2026

KCC2 Activation Reverses Neurophysiological and Behavioral Deficits in Female Rett Mice.

bioRxiv : the preprint server for biology
2026

Disease-modifying therapies for Rett syndrome: a review for neurologists.

Frontiers in neurology
2026

Profiling metabotropic glutamate receptor 7 expression in Rett syndrome: consequences for pharmacotherapy.

Neuroscience
2026

Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event reporting system (FAERS).

Frontiers in pharmacology
2026

Disrupted Vitamin D Signaling and Metabolism in Neurodevelopmental and Neurodegenerative Disorders.

ASN neuro
2026

Unexpectedly competent immune response to SARS-CoV-2 vaccination in Rett syndrome.

Human vaccines &amp; immunotherapeutics
2026

Development and Validation of the Korean Version of the Rett Syndrome Behavioral Questionnaire.

Children (Basel, Switzerland)
2026

Probing DNA damage in Rett syndrome neurons uncovers a role for MECP2 regulation of PARP1.

Stem cell reports
2026

Synaptic and intrinsic membrane defects disrupt early neural network dynamics in Down syndrome.

Nature communications
2025

Neurodegeneration Within the Spectrum of Pervasive Developmental Disorders.

Cureus
2026

Longitudinal analysis in Mecp2-het female mice reveals atypical nociceptive behaviours.

Journal of molecular medicine (Berlin, Germany)
2026

Whole exome sequencing facilitates early neurodevelopmental diagnosis in an outpatient clinic.

BMJ case reports
2026

Non-epileptic paroxysmal events in Rett syndrome: A systematic review of case-based and observational evidence.

Developmental medicine and child neurology
2026

Longitudinal Rett syndrome behaviour questionnaire scores and their associations with genotype and trajectories of mobility, weight and seizure frequency status.

Journal of neurodevelopmental disorders
2026

Loss of the Mecp2 gene in parvalbumin interneurons leads to an inhibitory deficit in the amygdala and affects its functional connectivity.

Molecular autism
2026

Methyl-CpG-binding protein 2 reads histone methylation via an aromatic cage to regulate gene expression and chromatin association.

The Journal of biological chemistry
2025

Pridopidine, a Potent and Selective Therapeutic Sigma-1 Receptor (S1R) Agonist for Treating Neurodegenerative Diseases.

Pharmaceuticals (Basel, Switzerland)
2026

Systemic administration of the OGT inhibitor OSMI-1 normalizes hippocampal O-GlcNAcylation and improves recognition memory, redox balance, and brain mitochondrial homeostasis in a Rett syndrome mouse model.

Free radical biology &amp; medicine
2025

Mecp2 deficiency impairs microscale cortical network topology and dynamics in a Rett syndrome mouse model.

bioRxiv : the preprint server for biology
2025

Pluripotent stem cells-based neural organoids for modelling human brain development and diseases.

Cell &amp; bioscience
2025

Trofinetide-Induced Enterocolitis Syndrome in a Child with Rett Syndrome.

Journal of child neurology
2025

Double Genetic Diagnosis Involving MECP2 and EPHB4 in a Child with Neurodevelopmental Delay and Vascular Anomalies: A Case Report.

Molecular syndromology
2025

MeCP2 regulates telencephalic development in human cerebral organoids.

Cell reports
2025

Brain assembloids decode human cortical networks in Rett syndrome.

Cell reports
2026

Doublecortin-expressing cells are selectively altered in the piriform cortex but not in neurogenic areas of symptomatic Mecp2-heterozygous mice.

Neuroscience
2025

Development and initial validation of the Communication Inventory Disability - Observer Reported (CID-OR): a measure of communication in CDKL5 deficiency disorder.

Journal of patient-reported outcomes
2025

MeCP2-driven chromatin organization controls nuclear stiffness.

Communications biology
2026

Reliability of Actigraphy for the Assessment of Sleep and Circadian Rhythms in Rett and Related Syndromes.

Journal of intellectual disability research : JIDR
2025

Mecp2 deficiency induces dysphagia in a preclinical model of Rett Syndrome.

bioRxiv : the preprint server for biology
2025

Breathing Dysfunction as a Meaningful and Measurable Aspect of Health in Rett Syndrome: A Caregiver's Perspective.

Digital biomarkers
2026

Pre-operative zoledronate is safe for children with medical complexity undergoing posterior spinal fusion for neuromuscular scoliosis.

Spine deformity
2025

MeCP2 interacts with the super elongation complex to regulate transcription.

Science advances
2025

Ganaxolone, an approved therapy for CDKL5-Deficiency Disorder, is an inhibitor of PTP1B.

bioRxiv : the preprint server for biology
2025

Astrocyte SEMA3C reduction improves Rett Syndrome phenotypes.

bioRxiv : the preprint server for biology
2025

Reciprocal regulation of the H3 histamine receptor in Rett syndrome and MECP2 Duplication syndrome: implications for therapeutic development.

bioRxiv : the preprint server for biology
2026

Living With Rett Syndrome: From Discovery to Clinical Advancements and Emerging Therapies.

Pediatric neurology
2025

Discovery and Tuning of RNA Editing Guides via High-Throughput Screening and Chemical Modification.

Chembiochem : a European journal of chemical biology
2025

Enhancing cognitive-motor recovery in Rett syndrome: effects of integrated intervention on neuropsychological and motor outcome.

Frontiers in psychology
2025

Epidemiology and Healthcare Resource Utilization of Rett Syndrome in Canada: The Ontario Experience.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
2025

Visual Recovery Reflects Cortical MeCP2 Sensitivity in Rett Syndrome.

Annals of clinical and translational neurology
2025

Tryptophan Metabolism in Neurodevelopment and Its Implications For Neurodevelopmental Disorders.

Molecular neurobiology
2026

Butyrate modifies epigenetic and immune pathways in peripheral mononuclear cells from children with neurodevelopmental disorders associated with chromatin dysregulation.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
2025

Differential effects of a single dose of Lisdexamfetamine and Guanfacine on cognitive function in children with ADHD.

Frontiers in psychiatry
2025

Atypical case of Rett syndrome with concurrent MECP2 gene mutation and del(15)(q22qter) karyotype: A case report and review of literature.

World journal of clinical pediatrics
2025

RNA-based therapies for neurodevelopmental disorders: innovative tools for molecular correction.

Frontiers in molecular biosciences
2025

miR-199a functions downstream of MeCP2 in neurons of MECP2 duplication syndrome models.

iScience
2025

Harnessing the microbiota-gut-brain axis to prevent and treat pediatric neurodevelopmental disorders: translational insights and strategies.

Journal of translational medicine
2025

Beyond Seizures as an Outcome Measure: A Global Severity Scoring System for CDKL5 Deficiency Disorder.

Brain and behavior
2025

A Systematic Review of Wearable Sensors in Rett Syndrome-What Physiological Markers Are Informative for Monitoring Disease States?

Sensors (Basel, Switzerland)
2025

The Ca2+ Bridge: From Neurons to Circuits in Rett Syndrome.

International journal of molecular sciences
2025

Altered activity of mPFC pyramidal neurons and parvalbumin-expressing interneurons during social interactions in a Mecp2 mouse model for Rett syndrome.

Journal of neurophysiology
2025

Mapping of neuronal redox conditions in a mouse model of Rett syndrome.

Neuroimage. Reports
2025

Ghrelin restores D1 receptor-mediated dopamine neurotransmission and enhances attentive behaviour in Mecp2 KO mice.

European journal of pharmacology
2025

The methyl-CpG-binding protein 2 inhibits cGAS-associated signaling.

Nature communications
2025

Risk of Ocular Pathology in Rett Syndrome.

Journal of pediatric ophthalmology and strabismus
2025

Predictors of aspiration, lower respiratory tract infection, and respiratory failure among individuals with Rett Syndrome: analysis of real-world claims data in the United States.

Frontiers in pediatrics
2025

MECP2T203M mutation disrupts neurogenesis in human cerebral organoids by altering chromatin dynamics and transcriptional regulation.

Science China. Life sciences
2025

Mecasermin for the treatment of Rett Syndrome: a systematic review.

Neurogenetics
2025

A Case Report: Co-Occurrence of TNRC6B Gene Variant and Xq28 Microdeletion Syndrome With Comprehensive Literature Review.

Birth defects research
2025

Prevalence, severity, frequency and healthcare resource use of epilepsy among individuals with Rett Syndrome: analysis of data from a Rett Center of Excellence.

Frontiers in neurology
2026

MECP2 Rare Variants in Boys With Central Precocious Puberty.

The Journal of clinical endocrinology and metabolism
2025

Quebec Spinal Muscular Atrophy Newborn Screening Program: The First Year Experience.

International journal of neonatal screening
2025

Real-world benefits and tolerability of trofinetide for the treatment of Rett syndrome: The LOTUS study.

Developmental medicine and child neurology
2025

Evaluating the utility of growth differentiation factor 15 and fibroblast growth factor 21 as blood biomarkers for Rett syndrome.

Scientific reports
2025

Communication and feeding skills in Rett syndrome: Case report.

Journal of intellectual &amp; developmental disability
2025

Optimized clonal isolation and immortalization of Rett syndrome patient fibroblasts for in vitro modeling of MECP2 mutations.

Scientific reports
2025

Mitochondrial redox imbalance and CoQ10 deficiency in Rett syndrome: Insights from patient-derived fibroblasts.

Archives of biochemistry and biophysics
2025

Identification and Treatment of Catatonia Presenting as Agitation and Self Injury in an Adolescent With Rett Syndrome.

Case reports in psychiatry
2025

Clinical and demographic characteristics of patients with autism spectrum disorder receiving general anesthesia with or without physical restraint: a single-center retrospective study.

Journal of anesthesia
2025

MeCP2 at the crossroads of hypoxia, oxidative stress, and gene regulation in Rett syndrome.

Epigenomics
2025

Atypical Rett syndrome with chorea: a case report.

Acta neurologica Belgica
2025

Rett Syndrome: The Epidemiology, Clinical Features, and Management.

Pediatrics in review
2025

Comprehensive in Silico Reclassification of MECP2 Variants of Uncertain Significance in Rett Syndrome: Performance Evaluation and Structural Analysis.

Journal of molecular neuroscience : MN
2025

Clinical application of radiofrequency echographic multi-spectrometry (REMS) for diagnosis and follow-up in several rare bone disorders: a case series.

BMC medical imaging
2025

Transcriptional Consequences of MeCP2 Knockdown and Overexpression in Mouse Primary Cortical Neurons.

International journal of molecular sciences
2025

Managing Complexity in Rett Syndrome with a Focus on Respiratory Involvement: A Tertiary Center Experience.

Children (Basel, Switzerland)
2026

Study of trofinetide in Rett syndrome: Lessons from an approved drug for a severe neurodevelopmental disorder.

Developmental medicine and child neurology
2025

Normalization of network activity in an epilepsy model with a constitutively active GABBR2 variant.

Brain : a journal of neurology
2025

Lipid peroxidation-induced cell death in Rett syndrome.

Free radical biology &amp; medicine
2025

Gait Analysis in Rett Syndrome: Integrating Linear and Nonlinear Techniques.

Journal of child neurology
2025

Adult-onset drug-resistant progressive epilepsy in a patient with novel MECP2 mutation.

Epileptic disorders : international epilepsy journal with videotape
2025

Translational reading frame determines the pathogenicity of C-terminal frameshift deletions in MeCP2: an alternative therapeutic approach.

bioRxiv : the preprint server for biology
2025

MECP2 Dysfunction in Rett Syndrome: Molecular Mechanisms, Multisystem Pathology, and Emerging Therapeutic Strategies.

International journal of molecular sciences
2025

Parent/caregiver perspectives of meaningful improvement in functional domains for people with CDKL5 deficiency disorder: a mixed-methods study.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
2025

HTA Evidence in Rare Diseases: Just Rare or Also Special?

PharmacoEconomics
2025

Clinical differences in monozygotic twins with Rett syndrome: case report and systematic review.

Orphanet journal of rare diseases
2025

Noonan Syndrome and Rett Syndrome in An 8-Year-Old Girl With A Tectal Neoplasm.

JCEM case reports
2025

Transduction of hematopoietic stem and progenitor cells by an MECP2 lentiviral vector improves Rett syndrome phenotypes.

Frontiers in drug discovery
2025

Exploring the uncharted role of cell senescence in rare diseases.

Orphanet journal of rare diseases
2025

Symptom Onset in Classic Rett Syndrome: Analysis of Initial Clinical Severity Scale Entries.

Annals of the Child Neurology Society
2025

Natural history of epilepsy in FOXG1 Syndrome.

Epilepsy research
2025

The Role of MLPA in Detecting Syndromic Submicroscopic Copy Number Variations in Normal QF-PCR Miscarriage Specimens.

Genes
2025

Mutation of MeCP2 at T158M Leads to Distinct Molecular and Phenotypic Abnormalities in Male and Female Mice.

Cells
2025

Safety Profiles of Trofinetide in Pediatric Rett Syndrome Population: A Real-World Postmarketing Pharmacovigilance Analysis.

Clinical therapeutics
2025

The associated factors of nutritional issues and body composition in Rett syndrome.

Journal of the Formosan Medical Association = Taiwan yi zhi
2025

Rett Syndrome: Specific MECP2 Variants are Associated With Elevated Serum Neurofilament Light Chain.

Pediatric neurology
2025

Exosomal microRNAs in common mental disorders: Mechanisms, biomarker potential and therapeutic implications.

World journal of psychiatry
2025

Astrocytic Regulation of aberrant perineuronal net formation in Mecp2 -null Neocortex.

bioRxiv : the preprint server for biology
2026

Outcomes of Growth-Friendly Surgery and Posterior Spinal Fusion in Children With Rett Syndrome and Early Onset Scoliosis.

Journal of pediatric orthopedics
2025

Altered oscillatory coupling reflects possible inhibitory interneuron dysfunction in Rett syndrome.

medRxiv : the preprint server for health sciences
2025

Cortical Visual Impairment Across a Range of Neurodevelopmental Disorders: Clinical Characterization, Diagnostic Tool Evaluation, and Association with Developmental Outcomes.

Journal of child neurology
2025

Clinical and genetic characteristics associated with dual-positive gene variations.

Frontiers in neuroscience
2025

Post-encephalitic epilepsy in patients with acute encephalopathy with biphasic seizures and late reduced diffusion.

Frontiers in neurology
2025

Genetic implication of GABAB receptors in the etiology of neurological and psychiatric disorders.

Frontiers in pharmacology
2025

Evidence of neuronal DNA damage in the brains of patients with Rett syndrome.

Disease models &amp; mechanisms
2025

Genotype-Phenotype Correlation and Therapeutic Amenability in a Cohort of Rett Syndrome Patients: A Single-Center Study.

Cureus
2025

At-School Telerehabilitation for Rett Syndrome: Support Teachers Driving Cognitive and Communication Progress in a Randomized Trial.

Children (Basel, Switzerland)
2025

Sleep Disorders in Children with Rett Syndrome.

Children (Basel, Switzerland)
2025

Communication Abilities, Assessment Procedures, and Intervention Approaches in Rett Syndrome: A Narrative Review.

Brain sciences
2025

Attenuated orexinergic signaling underlies sleep-wake problems in a Mecp2-null mouse model of Rett syndrome.

Neurobiology of disease
2025

Conformational flexibility and rotational binding shifts in W104C mutant MECP2-DNA complexes: A molecular simulation study.

Biochemical and biophysical research communications
2025

Rett syndrome: Pathogenicity and regulation of MECP2 (human) and Mecp2 (mouse) genes and their protein products through various molecular mechanisms.

Mutation research. Reviews in mutation research
2025

Rett syndrome: a complex disorder with promising therapeutic prospects.

Trends in molecular medicine
2025

Do young people get the mental healthcare they need? Trajectories of depressive symptoms, correlates and care pathways in a clinical sample of young people reaching the upper age limit of their CAMHS.

Journal of affective disorders
2025

Persistent Disruptions in Prefrontal Connectivity Despite Behavioral Rescue by Environmental Enrichment in a Mouse Model of Rett Syndrome.

The Journal of comparative neurology
2025

Genomic insights into Rett syndrome-like features in Bangladeshi participants.

Genetics in medicine open
2025

Directed evolution expands CRISPR-Cas12a genome-editing capacity.

Nucleic acids research
2025

Early transcriptional signatures of MeCP2 positive and negative cells in Rett syndrome.

bioRxiv : the preprint server for biology
2025

5-mC DNA methylation in neurodevelopment: from molecular mechanisms to therapeutic implications.

Molecular biology reports
2025

Growth, Feeding and Nutrition in Rett Syndrome: Retrospective Audit of Twenty Years' Experience From an Australian Multidisciplinary Management Clinic.

Journal of paediatrics and child health
2025

Overexpression of mGlu7B in Mice: Implications for Neurodevelopmental Disorders.

Molecular neurobiology
2025

Cannabidivarin mitigates motor and cognitive impairments in a female mouse model of Rett syndrome.

Life sciences
2025

Altered dendritic morphology of MEC II pyramidal and stellate cells in Rett syndrome mice.

Frontiers in neuroanatomy
2025

Rett syndrome: advances in Understanding MeCP2 function, potential gene therapies, and public health implications.

Molecular biology reports
2025

[Analysis of MECP2 gene variants and X chromosome inactivation in four children with Rett syndrome].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2025

Targeting microRNA-dependent control of X chromosome inactivation improves the Rett Syndrome phenotype.

Nature communications
2025

MeCP2 prevents against sustained ketamine-induced synaptic depression at inhibitory synapses.

iScience
2025

Case Report: Diagnostic assessment, developmental trajectory and treatment approaches in a case of a complex neurodevelopmental syndrome associated with non- synonymous variants in MECP2 (p. R133C) and GABBR1.

Frontiers in pediatrics
2025

Clinical and functional outcomes in pediatric patients with Rett syndrome: a 15-year retrospective study.

European journal of pediatrics
2025

Loss of MeCP2 leads to sleep deficits that are time-of-day dependent and worsen with sleep deprivation.

Neurobiology of sleep and circadian rhythms
2025

Zebrafish mecp2 null-mutation increases anxiety and cortisol levels but no change in adult social preference and larval chemically-induced hyperlocomotion.

BMC neuroscience
2025

AI-enabled drug prediction and gene network analysis reveal therapeutic use of vorinostat for Rett Syndrome in preclinical models.

Communications medicine
2025

Development of a BRET based chloride biosensor for high throughput screening of KCC2 modulators.

SLAS discovery : advancing life sciences R &amp; D
2025

Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) Improves Symptoms of Rett Syndrome: An Open-Label Study.

Journal of paediatrics and child health
2026

Sleep Problems and Clinical Severity in Rett Syndrome.

Journal of child neurology
2025

Overcoming Challenges in Learning Prerequisites for Adaptive Functioning: Tele-Rehabilitation for Young Girls with Rett Syndrome.

Journal of personalized medicine
2025

Considerations and procedures for acquiring EEG as part of multi-site studies for Rett syndrome and other genetic neurodevelopmental disorders.

Frontiers in integrative neuroscience
2025

Revealing function-altering MECP2 mutations in individuals with autism spectrum disorder using yeast and Drosophila.

Genetics
2025

Is highly purified cannabidiol a treatment opportunity for drug-resistant epilepsy in subjects with typical Rett syndrome and CDKL5 deficiency disorder?

Epilepsia open
2026

Mitochondrial dynamics dysfunction and neurodevelopmental disorders: From pathological mechanisms to clinical translation.

Neural regeneration research
2025

Altered Microglial Plasticity in the Periaqueductal Grey of Pre-Symptomatic Mecp2-Heterozygous Mice Following Early-Life Stress.

Neuromolecular medicine
2025

Medical Biases and Misconceptions Impact Diagnoses in Males With Loss of Function MECP2 Variants.

American journal of medical genetics. Part A
2025

Genetic abnormalities in catatonia: a systematic review.

Psychological medicine
2025

Molecular Insights into Neurological Regression with a Focus on Rett Syndrome-A Narrative Review.

International journal of molecular sciences
2025

Female cortical cellular mosaicism underlies shared MeCP2 and PCB impacted gene pathways.

bioRxiv : the preprint server for biology
2025

Integrative analysis of 115 transcriptomic studies decodes the molecular landscape of neurodevelopmental disorders.

Communications biology
2025

CHD8 Variant and Rett Syndrome: Overlapping Phenotypes, Molecular Convergence, and Expanding the Genetic Spectrum.

Human mutation
2026

Bilingualism in the preserved speech variant of Rett syndrome: A longitudinal case study.

Clinical linguistics &amp; phonetics
2025

Parkinsonism and Dystonia Are Prevalent and Concomitant Movement Disorders in a Cohort of Patients with Rett Syndrome.

Movement disorders clinical practice
2025

Impaired persistence of cortical sensory adaptation following repetitive tactile stimulation in the hindlimb somatosensory cortex of Rett syndrome mice.

Neuroscience
2025

Potentiation of group III metabotropic glutamate receptors positively affects neurophysiological features in a mouse model of Rett syndrome.

The Journal of pharmacology and experimental therapeutics
2025

Rett Syndrome: Thinking Beyond Brain Borders.

Advances in experimental medicine and biology
2025

Neuronal Plasticity-Dependent Paradigm and Young Plasma Treatment Prevent Synaptic and Motor Deficit in a Rett Syndrome Mouse Model.

Biomolecules
2025

MECP2 mRNA Profile in Brain Tissues from a Rett Syndrome Patient and Three Human Controls: Mutated Allele Preferential Transcription and In Situ RNA Mapping.

Biomolecules
2025

A Computational Approach to Identify Novel Protein Targets Uncovers New Potential Mechanisms of Action of Mirtazapine S(+) and R(-) Enantiomers in Rett Syndrome.

Journal of neurochemistry
2025

Exploring the Genetic Role of MECP2 Mutations on Phenotypic Presentation in Males: A Case Report.

Journal of developmental and behavioral pediatrics : JDBP
2025

MECP2 duplication syndrome: Recent advances in pathophysiology and therapeutic perspectives.

Brain &amp; development
2025

Current and Emerging Precision Therapies for Developmental and Epileptic Encephalopathies.

Pediatric neurology
Ver todos os 2.859 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Síndrome Rett.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Síndrome Rett

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Dysregulated Cholesterol Clearance via CYP46A1 Contributes to Cerebellar Sterol Imbalance in Mecp2-Null Mice.
    International journal of molecular sciences· 2026· PMID 41828569mais citado
  2. MECP2-Associated Rett Syndrome Without Developmental Regression-A Case Series.
    Journal of child neurology· 2026· PMID 41818639mais citado
  3. A KCNC1 variant linked to Rett syndrome disrupts ER to Golgi trafficking of Kv3.1 channel.
    Proceedings of the National Academy of Sciences of the United States of America· 2026· PMID 41818146mais citado
  4. A novel heterozygous pathogenic variation in the MECP2 gene causing typical Rett syndrome: a case report.
    Translational pediatrics· 2026· PMID 41810194mais citado
  5. Safety and effectiveness of diazepam nasal spray in patients with Rett syndrome and seizure clusters: post hoc analyses from a long-term safety study and survey of severity and burden.
    Frontiers in neurology· 2026· PMID 41809194mais citado
  6. Mecp2 deficiency induces dysphagia in a preclinical model of Rett syndrome.
    Proc Natl Acad Sci U S A· 2026· PMID 41989852recente
  7. Decoding MeCP2 in pain: a systematic review of mechanisms, dosage, and clinical implications.
    Neurosci Biobehav Rev· 2026· PMID 41985644recente
  8. Early differential impact of MeCP2 mutations on functional networks in Rett syndrome patient-derived human cortical organoids.
    Nat Commun· 2026· PMID 41980938recente
  9. From Gene to Hope: Rett Syndrome and the Rise of Molecular Therapies.
    Mol Diagn Ther· 2026· PMID 41975033recente
  10. Pilot study: the impact of simulation-based pediatric basic life support training on the performance of caregivers of children with Rett syndrome.
    BMC Med Educ· 2026· PMID 41963928recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:778(Orphanet)
  2. OMIM OMIM:312750(OMIM)
  3. MONDO:0010726(MONDO)
  4. GARD:5696(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Artigo Wikipedia(Wikipedia)
  8. Q917357(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Síndrome Rett
Compêndio · Raras BR

Síndrome Rett

ORPHA:778 · MONDO:0010726
Prevalência
1-9 / 100 000
Herança
X-linked dominant
CID-10
F84.2 · Síndrome de Rett
CID-11
Ensaios
28 ativos
Medicamentos
11 registrados
Início
Infancy
Prevalência
10.0 (Europe)
MedGen
UMLS
C0035372
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades